Prostate cancer Cancer
Conditions
Interventions
The participant will undergo three imaging tests: CT, bone scan, and PSMA PET-CT. After completing all imaging tests, they will be randomly allocated to one of two groups. The participant will have an
Sponsors
Imperial College London
Eligibility
Sex/Gender
Male
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed prostate adenocarcinoma 2. NCCN high-risk cancer defined as any of: 2.1. Stage >/= cT3 OR 2.2. ISUP Grade Group 4 and 5 (or Gleason score 8, 9 or 10) OR 2.3. PSA >20 ng/ml 3. M0 on standard prostate MRI 4. Patient suitable for standard local therapy (surgery or radiotherapy with curative intent) to the prostate as deemed by clinical team 5. Age >= 18 years
Exclusion criteria
Exclusion criteria: 1. M1 on standard prostate MRI 2. Unable to undergo prostate/pelvic MRI, CT-TAP, radio-isotope bone-scan, or PSMA PET-CT 3. Unable to receive iodinated contrast (eg contrast allergy, significant renal impairment) 4. Previous imaging, other than screening pelvic MRI, for the primary purpose of staging pelvic nodal or distant metastatic disease of prostate cancer within 8 weeks prior to randomisation 5. Previous local or systemic (including any ADT/ARTA/docetaxel chemotherapy) treatment of prostate cancer (5-alpha reductase inhibitors are permitted) 6. Other malignancies diagnosed in previous 2 years (except non-melanoma skin cancer) 7. Variant/non-adenocarcinoma histology (e.g., spindle cell, neuroendocrine) 8. Already commenced hormone treatment
Countries
United Kingdom
Contacts
Public ContactSamuel;. Morris;General clinical enquires
;
Outcome results
None listed